PharmaCyte Biotech Inc (PMCB)

[Triple9]

Protocols for Phase 1 aka Safety Studies for Oncology are to test on people who actually have the cancer. $PMCB's upcoming trial is targeting people who are no longer responding to regular chemotherapy.

So, again, the FDA is going to tell PMCB to inject these people with CiaB, but not to activate it? Man, that seems really cold.

The studies were published in 2014: http://www.mdpi.com/1999-4923/6/3/447/htm

Moreover, there was a recent study in China 2016: http://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0179279. Why wouldn't the FDA accept data from that?